

Supplementary Table 5. Injection-site adverse experiences by maximum intensity

Injection-site AE	9vHPV Vaccine injection site Following vaccination 1		9vHPV vaccine injection site Following Any Vaccination		Tdap-IPV Vaccine Injection Site Following vaccination	
	Concomitant administration	Non-concomitant administration	Concomitant administration	Non-concomitant administration	Concomitant administration	Non-concomitant administration
	(Group A) ^a	(Group B) ^a	(Group A) ^a	(Group B) ^a	(Group A) ^a	(Group B) ^a
Number of subjects with follow-up	524	527	525	527	525	520
Number (%) of subjects with the following injection-site AEs:						
Pain	310 (59.2)	319 (60.5)	445 (84.8)	441 (83.7)	454 (86.5)	435 (83.7)
Mild	244 (46.6)	255 (48.4)	249 (47.4)	276 (52.4)	236 (45.0)	196 (37.7)
Moderate	61 (11.6)	60 (11.4)	172 (32.8)	144 (27.3)	182 (34.7)	186 (35.8)
Severe	5 (1.0)	4 (0.8)	24 (4.6)	21 (4.0)	36 (6.9)	53 (10.2)
Swelling	68 (13.0)	43 (8.2)	213 (40.6)	164 (31.1)	207 (39.4)	163 (31.3)
Mild (0 to ≤2.5 cm)	54 (10.3)	33 (6.3)	138 (26.3)	112 (21.3)	107 (20.4)	80 (15.4)
Moderate (>2.5 cm to ≤5.0 cm)	7 (1.3)	6 (1.1)	46 (8.8)	35 (6.6)	45 (8.6)	36 (6.9)
Severe (>5.0 cm)	7 (1.3)	4 (0.8)	29 (5.5)	17 (3.2)	54 (10.3)	47 (9.0)
Unknown	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.2)	0 (0.0)
Erythema	43 (8.2)	30 (5.7)	160 (30.5)	127 (24.1)	141 (26.9)	113 (21.7)
Mild (0 to ≤2.5 cm)	35 (6.7)	27 (5.1)	119 (22.7)	107 (20.3)	63 (12.0)	49 (9.4)
Moderate (>2.5 cm to ≤5.0 cm)	7 (1.3)	1 (0.2)	27 (5.1)	10 (1.9)	28 (5.3)	28 (5.4)
Severe (>5.0 cm)	1 (0.2)	2 (0.4)	14 (2.7)	10 (1.9)	50 (9.5)	36 (6.9)

^aGroup A (concomitant administration) received a 0.5 mL dose of 9vHPV vaccine at day 1, month 2, and month 6 and a 0.5 mL dose of Tdap-IPV vaccine on day 1; Group B (non-concomitant administration) received 9vHPV vaccine as above and Tdap-IPV vaccine at month 1. One subject who was randomized into the Non-concomitant Group received 9vHPV vaccine at day 1 but did not receive Tdap-IPV at Month 1 and is excluded from this table.